Vitiligo News

Makeup not only has cosmetic applications, but medical ones too.

Incyte has launched the Vitiligo Innovators Program to honor exceptional individuals who have made significant contributions to the vitiligo community, according to a company press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

The first subject has been dosed in a phase 2b trial evaluating VYN201 for the treatment of active or stable nonsegmental vitiligo.

Safety data for ruxolitinib cream, a Janus kinase inhibitor, in the first year after its approval has shown that the drug is generally well tolerated for the treatment of atopic dermatitis or vitiligo, according to a postmarketing review.

Healio has compiled April’s most-read news in dermatology.

Healio has compiled March’s most-read news in dermatology.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

SAN DIEGO — Patients with nonsegmental vitiligo continually improved with upadacitinib treatment up to 1 year, according to a speaker at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — In patients with active nonsegmental vitiligo, ritlecitinib monotherapy or paired with twice weekly narrowband ultraviolet B phototherapy improved facial and total body repigmentation, according to a speaker here.